Vanguard Capital Management
ACTU

Vanguard Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Vanguard Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602K Sell
393,433
-7,096
-2% -$16.4K ﹤0.01% 3684
2026
Q1 		$1.1M Buy
+400,529
New +$1.66M ﹤0.01% 3524

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
RCG
Rock Creek Group Washington, District of Columbia $994M AUM 11.29% 1-Year Est. Return

Vanguard Capital Management's ACTU Position: Q2 2026 in Review

Vanguard Capital Management reduced its Actuate Therapeutics (ACTU) stake by 1.8% in Q2 2026, selling an estimated $16.4K and leaving 393,433 shares worth $602K. The position accounts for ﹤0.01% of the portfolio, ranked #3684.

Vanguard Capital Management first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.1M in Q1 2026. 62 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Vanguard Capital Management held 393,433 shares of Actuate Therapeutics worth $602K as of Q2 2026.
  • Vanguard Capital Management sold 7,096 Actuate Therapeutics shares in Q2 2026, an estimated $16.4K.
  • Actuate Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3684 holding.
  • Vanguard Capital Management first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Actuate Therapeutics position peaked at $1.1M in Q1 2026.
  • 62 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.